Pall opens Center of Excellence in Shanghai
The CoE showcases the latest end-to-end technological solutions for biomanufacturing.
Pall Corporation has established a Biotech Integrated Solutions Center of Excellence (CoE) in Shanghai, China. Strategically located in the heart of Shanghai’s renowned life science cluster, the CoE is a new state-of-the-art facility for bioprocess engineering consultancy, technology demonstration, testing and training for China and broader Asia.
Equipped with advanced bioprocessing equipment and automation platforms, the CoE showcases the latest end-to-end technological solutions for biomanufacturing, including single-use cell culture solutions, cell clarification using acoustic wave technology, chromatography using automated packing techniques, viral clearance, tangential flow filtration and mixer/container modules. It is designed to lead Pall’s customers through the sequential stages of process flow and will serve as a proving ground for new technologies, as well as a training facility for Pall customers and Pall employees.
“As the biopharmaceutical industry moves from traditional batch or single-use processing to continuous bioprocessing solutions, Pall is poised to help customers reduce process development and production costs and drive significant improvements in efficacy and productivity,” President of Pall Corporation, Jennifer Honeycutt, explained.
“Our investment in the new Shanghai CoE is designed to give Pall customers options ranging from batch to single use and continuous bioprocessing solutions, depending upon where customers are in their journey. The goal is to provide technology solutions that meet their current needs, while offering some of the most progressive technological solutions for the future,” added Honeycutt. “By opening this state-of-the-art facility, we hope to unlock new opportunities for our customers based in China, and for any global customers looking to enter or expand their operations in the Asia Pacific region.”
Pall Biotech has invested heavily in a growing network of CoE facilities worldwide to support its global biopharmaceutical customer base. Three CoE facilities currently exist in Portsmouth (UK), Westborough (USA), and Shanghai (China), with planning for a new European facility in process.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance